BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report)’s stock price traded down 3.8% during mid-day trading on Wednesday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68. The company has a 50 day simple moving average of C$10.60 and a 200-day simple moving average of C$10.60. The stock has a market capitalization of C$168.68 million and a P/E ratio of -28.19.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Want to Profit on the Downtrend? Downtrends, Explained.
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- What is a Low P/E Ratio and What Does it Tell Investors?
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
